Cancer Genetics, Inc.

NASDAQ: CGIXHealthcare / Medical Laboratories & Research / USA
0.1700+0.0100+6.25%Vol 796 0521Y Perf -82.79%
Jun 20th, 2019 15:59
BID0.1700 ASK0.1700
Open0.1700 Previous Close0.1600
Pre-Market0.17 After-Trading-
 0.01 6.25%  - -%
Target Price
4.50 
Analyst Rating
— 0.00
Potencial %
2 547.06 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/100/100 
Value Ranking
     26.78
Insiders Value % 3/6/12M
-/100/100 
Growth Ranking
     27.98
Insiders Shares Cnt. % 3/6/12M
-/100/100 
Income Ranking
 —    -
Market Cap (mil)10 
Earnings Rating
Buy
Price Range Ratio 52wk %
1.74 
Earnings Date
13th Aug 2019

Today's Price Range

0.16000.1700

52wk Range

0.15001.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Month
0.00%
3 Months
-37.04%
6 Months
-51.43%
1 Year
-82.79%
3 Years
-91.46%
5 Years
-98.48%

Name / TickerPriceChg.Chg.%
CGIX0.17000.01006.25
AAPL199.461.59000.80
GOOG1 111.429.09000.82
MSFT136.951.26000.93
XOM76.611.29001.71
WFC45.860.21000.46
JNJ142.211.76001.25
FB189.532.05001.09
GE10.630.29002.80
JPM110.190.28000.25
Earnings HistoryEstimateReportedSurprise %
Q01 2019--0.08-
Q04 2018--0.14-
Q03 2018-0.16-0.23-43.75
Q02 2018-0.13-0.130.00
Q01 2018--0.16-
Q04 2017--0.35-
Q03 2017-0.13-0.16-23.08
Q02 2017-0.16-0.160.00
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.070.00-
6/2019 QR-0.050.00-
12/2019 FY-0.110.00-
12/2019 FY-0.11--
Next Report Date13th Aug 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume796 052
Shares Outstanding (in ths.)57 816
Trades Count607
Dollar Volume131 895
Avg. Volume1 900 105
Avg. Weekly Volume642 129
Avg. Monthly Volume1 018 572
Avg. Quarterly Volume1 474 555
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
1 (100.00 %)
2 (50.00 %)
Moderate Buy
0
0 (0.00 %)
0 (0.00 %)
Hold
0
0 (0.00 %)
2 (50.00 %)
Moderate Sell
0
0 (0.00 %)
0 (0.00 %)
Strong Sell
0
0 (0.00 %)
0 (0.00 %)
Rating-Strong Buy
1.00
Moderate Buy
2.00

Cancer Genetics, Inc.

Cancer Genetics Inc is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular markers. The company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. It also enables biotech and pharmaceutical companies to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company derives most of its revenue from the United States.

CEO: John A. Roberts

Teplephone: +1 201 528-9200

Address: 201 Route 17 North, Rutherford 07070, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

40%60%

Bearish Bullish

35%65%

Bearish Bullish

69%31%

News